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Errata
In the Summer 2016 issue of the Quarterly (vol. 10, no. 3, 
page 7), Table 4 listed a combined treatment that included 
taking sertraline for 2 weeks. Correction as of November 2016 
clarified that sertraline was taken for 12 weeks.
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When inattention interferes 
Most children develop the ability to regulate their behaviour without serious difficulties, for example, learning to pay attention, sit quietly and think before acting. Some children, however, experience challenges with inattention, hyperactivity and impulsivity — to a degree that interferes 
with their development and success at home, at school or in the community. In these cases, a diagnosis of 
attention-deficit/hyperactivity disorder (ADHD) may need to be considered.
Diagnostic decision-making
Prior to making a diagnosis, qualified practitioners should conduct a thorough assessment, 
preferably working in interdisciplinary teams. Such an assessment should include carefully 
interviewing children and caregivers to determine the history, frequency, severity and 
impact of the symptoms as well as potential causes.
In particular, inattention, hyperactivity or impulsivity must exceed what is expected 
given the child’s developmental stage. As well, symptoms must interfere with the child’s 
functioning in multiple settings (e.g., both at home and at school). It is important to 
also ascertain that symptoms are actually due to ADHD rather than to another mental 
disorder such as anxiety, or to learning difficulties, or to adverse circumstances such as child 
maltreatment. In addition to interviewing children and caregivers, many practitioners will ask caregivers and 
teachers to complete standardized questionnaires about the child’s behaviours. As well, children may be asked 
to complete tests of attention. 
Some children experience challenges with inattention, hyperactivity and impulsivity — to a degree that interferes with 
their development and success at home, at school or in the community.
ov e r v i e w
A careful and 
comprehensive 
assessment is essential 
to ensure that children 
who are diagnosed 
with ADHD actually 
have the disorder.
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A careful and comprehensive assessment is essential to ensure that children who are diagnosed with 
ADHD actually have the disorder. Considerable harm can result when inappropriate ADHD diagnoses lead 
to unnecessary treatment, and such diagnoses may also cause unnecessary distress for children and families. 
Harm can also result when other conditions are mistaken for ADHD, if these underlying conditions do not 
get addressed. Table 1 describes the criteria for diagnosing ADHD.
ov e r v i e W
Thinking about causation
identifying what causes a disorder typically begins by determining which factors are associated or correlated 
with the disorder. the next step involves determining 
which of these factors precede the disorder. Beyond this 
a causal risk factor is defined even more rigorously — as 
a modifiable factor that changes the outcome, such as 
adhd, when you manipulate it with interventions.3, 6  
Why do these distinctions matter? if we erroneously 
focus on factors that are not truly causal, we divert time 
and resources away from searching for and addressing 
factors that can really make a difference for children.2 
in addition, focusing on single factors, whether genetic 
or environmental, overlooks the now-overwhelming 
research evidence that genes and environment do 
not operate independently.2 so, beyond seeking 
and addressing causal risk factors, researchers and 
practitioners must always consider the role of gene-
environment interplay in causation, particularly when 
designing interventions for children.
Table 1: Diagnostic Criteria for ADHD1  
Inattention 
•  Difficulty sustaining attention
•  Easily distracted
•  Forgetful in daily activities
•  Makes careless mistakes/poor attention to detail
•  Challenges listening
•  Problems following instructions
•  Difficulties organizing tasks or activities
•  Avoids tasks needing sustained mental effort
•  Loses needed items
ADHD involves a persistent pattern of inattention and/or hyperactivity that interferes with functioning or development. 
For a diagnosis, six or more symptoms must persist over six or more months, symptoms must be present before age 
12 years, and symptoms must be inconsistent with developmental level. Other contributing potential causes must also 
be ruled out, e.g., underlying anxiety disorders or child maltreatment.
Hyperactivity and Impulsivity 
•  Frequently fidgets or squirms
•  Difficulty remaining seated
•  Excessive running or climbing about
•  Challenges playing quietly
•  Excessive talking
•  Blurts out answers
•  Problems with taking turns
•  Interrupts others
•  Restlessness/difficulties being still
What causes ADHD?
A recent high-quality review has summarized the evidence on the possible causes of ADHD.2 After carefully 
considering the available research, the authors identified a number of important risk factors for ADHD — 
both genetic and environmental. (For something to be deemed a risk factor, it must occur before the disorder 
is developed. To be deemed a causal risk factor, there must be evidence showing that modifying the risk factor 
actually changes whether the disorder develops.)3
The authors found strong evidence that ADHD runs 
in families, with individuals who have first-degree relatives 
with ADHD being two to eight times more likely to 
have the disorder.2 Importantly, this increased risk due to 
family history can involve both genetic and environmental 
factors — as well as the interactions between them. For 
example, genetic vulnerability can alter an individual’s 
sensitivity to environmental risk and protective factors.
The review also identified a number of gene and 
chromosomal variations implicated in ADHD.2 Even so, 
the individual effects of identified genetic variations were 
very small.2 As well, the identified chromosomal variants 
were not unique to individuals with ADHD. They were also 
found among some children without ADHD and were not 
always present among children with ADHD.2 As a result, 
neither gene nor chromosomal risk factors have the level of 
evidence needed to identify them as causing ADHD.2
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The authors also identified many environmental risk factors for ADHD. Prenatal factors included exposure 
to nicotine, alcohol and other substances as well as maternal stress.2 Perinatal factors included low birth weight 
and prematurity.2 Environmental toxins included exposure to lead, pesticides such as organophosphates and 
industrial products such as polychlorinated biphenyls.2
Although the review authors concluded that none of the identified risk factors had 
consistent and strong enough evidence to be identified as causing ADHD, they found one 
item that reached the threshold of a likely causal risk factor: early and severe deprivation in 
childhood.2 For example, they described children raised in Romanian orphanages in the 
1980s. There, deprivation was so severe that many children lacked absolute essentials such 
as adequate heating, water, nutrition and basic care.4 This evidence was deemed stronger 
than the evidence for the other risk factors. The research included quasi-experimental data 
comparing long-term outcomes for children from the Romanian orphanages who were later 
adopted by British families to British children who were also adopted but who had not experienced a deprived 
institutional rearing. This “natural experiment” found that the Romanian adoptees had much higher rates of 
inattention and overactivity at age six than British adoptees.5 At age 11, only the Romanian adoptees who had 
been adopted after age six months continued to show elevated levels of inattention and hyperactivity.5
Knowing about risks and building resiliency
The best available evidence suggests that many different risks can lead to the development of ADHD.2 And 
the identification of these risk factors has important implications. This knowledge can inform new efforts to 
prevent ADHD as well as guide existing prevention interventions, such as those identified in our previous 
issue. Additionally, this information can help direct more general efforts to promote children’s well-being, 
including supporting women to have pregnancies that are substance free and with minimal stress. Even with 
such efforts, however, some children will still develop ADHD and will require effective treatments. The 
Review article that follows identifies a range of interventions with proven success for children.
Forty years of  
research have  
shown that many 
effective treatments 
exist for childhood 
ADHD.
ov e r v i e W
The best available evidence suggests that many different risks can lead to the development of ADHD.
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A guide to ADHD medications
Medications used to treat childhood adhd are sold in Canada under various names, which are 
summarized in the table below. the effects of “short-
acting” versions typically last several hours, while 
effects of “long-acting” versions typically last twice 
as long (e.g., up to eight or 10 hours), meaning that 
medication benefits can be more stable.10
Compelling choices for treating 
childhood ADHD 
At any given time, approximately 2.5% of Canadian children — or nearly 17,000 in BC — meet diagnostic 
criteria for attention-deficit/hyperactivity 
disorder (ADHD).7 For these children to reach  
their full potential, they need effective 
treatments. Our past reviews of the research  
have identified several options with strong 
evidence of success.
In our Fall 2007 issue, we reviewed three 
medications commonly used to treat ADHD: 
methylphenidate, dextroamphetamine and 
atomoxetine. (Their brand names are listed in the 
sidebar.) The systematic review we featured found 
that all three medications effectively reduced 
ADHD symptoms and improved children’s quality of life — despite all being associated with side effects, 
including decreased appetite, insomnia, headache and stomachache.8 
In that issue and in our Spring 2013 issue, we also identified several effective psychosocial treatments, 
including behavioural and cognitive-behavioural therapy 
(CBT) for children, and behavioural training for parents.8–9 
Even so, children had better outcomes when these treatments 
were combined with medications.8–9 Equally important, we 
also identified several treatments with no rigorous evidence 
supporting their use. These included dietary modifications, 
such as polyunsaturated fatty acids, as well as homeopathy,  
pet therapy and play therapy.8–9
Building on our knowledge base 
To identify newer ADHD treatments, we conducted a 
targeted search and review of randomized controlled trials 
(RCTs). Given that we have already extensively analyzed the 
three most commonly used ADHD medications, we limited 
our medication search to guanfacine.11 We did this because in 
2013, Health Canada approved guanfacine as a treatment for 
ADHD in children aged six to 12 years — both on its own 
and as an adjunctive therapy for children with suboptimal 
responses to psychostimulant medications.13 We also 
conducted a separate search for RCTs evaluating psychosocial 
treatments and dietary supplements published between 
ADHD Medications11–12 
Psychostimulants 
Non-psychostimulants 
Generic name 
Methylphenidate 
 
dextroamphetamine
atomoxetine
Guanfacine
Brand name 
Biphentin
Concerta
ritalin
adderall 
dexedrine
Vyvanse
strattera
intuniv
The evidence supporting child CBT and behavioural therapy is 
particularly strong, spanning many studies now, and evidence on 
neurofeedback is also starting to emerge.
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2011 and 2016. We limited our search to five years to 
ensure that we captured newer RCTs, updating our most 
recent previous review. Based on these two searches, we 
retrieved and assessed 88 RCTs, six of which met our 
inclusion criteria (detailed in the Methods). Two RCTs 
evaluated guanfacine and four evaluated psychosocial 
interventions.14–21
For guanfacine, one RCT assessed the medication 
independently and one assessed it as an adjunctive 
therapy in six- to 17-year-olds.14–16 The RCT assessing guanfacine as an adjunctive therapy focused on children 
who had experienced some improvement on extended-release forms of psychostimulants (methylphenidate 
or dextroamphetamine products) but who still had mild to moderate ADHD symptoms and at least some 
functional impairment.15 All children in this study remained on their usual ADHD medication (i.e., 
methylphenidate or dextroamphetamine products) and in addition, were randomly assigned to also receive 
either guanfacine or a placebo.15 Notably, the drug manufacturer was heavily involved in design, data 
collection, analyses and interpretations for both studies. As well, all study authors had financial ties to the 
drug manufacturer. Table 2 provides additional information about these two RCTs. 
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A newer use for an older medication
Guanfacine, a selective alpha-2 agnostic, is a medication that has long been used to reduce blood pressure in 
adults with hypertension.13 While its precise mechanism 
of action for adhd is unknown, it is thought to activate 
receptors for neurotransmitters such as noradrenaline.14, 22 
Because it has only recently been used to treat childhood 
adhd, the long-term effects of this medication for young 
people are unknown.
 
Table 2: Guanfacine Evaluations
Child  
ages
6 –17 years
 
 
6 –17 years 
Sample  
size
338
 
 
461
Program 
(Country)
Guanfacine alone 14 
(Us, Canada + 11 
european countries)
Guanfacine adjunctive  
to a psychostimulant 15 
(Us)
Delivery
(total time on medication)
dose increased over 4 –7 weeks, then maintained for 6 weeks, 
followed by 2-week tapering off period  
(12 weeks for 6 –12 year olds; 15 weeks for 13–17 year olds)*
dose increased over 5 weeks, then maintained for 3 weeks, 
followed by 1- week tapering off period  
(9 weeks)*  
* Final side effect assessments occurred 7 days14 or 7–9 days15 after the final medication dose.
Other approaches for treating childhood ADHD 
The four accepted psychosocial RCTs assessed five different interventions — three delivered to children and 
two focused on parents.17–20 All three child programs worked to cultivate specific cognitive skills, such as 
attention and memory, using computer games. 
The first child-focused RCT evaluated Braingame Brian, which aimed to increase executive functioning 
skills — including improving memory and cognitive flexibility and decreasing impulsive responding.17 
Children were randomized to participate in either the full version of Braingame Brian (where the difficulty  
of all tasks was automatically adjusted to the child’s performance level), a “partial” version (where the  
difficulty of memory tasks, specifically, remained stable) or a placebo condition (where the difficulty of all 
tasks remained stable). All children completed 25 sessions, each lasting 35 to 50 minutes, using computers  
at home over a five-week period, supported by weekly phone calls to monitor progress.
The second child-focused RCT compared two different approaches — neurofeedback and cognitive 
training — to a waitlist control condition.18 In the neurofeedback group, children were trained to increase 
their attention skills by altering two specific types of brain waves. Specifically, children learned to increase beta 
waves, which are associated with being alert and focused, and decrease theta waves, which are associated with 
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relaxation.18 Children received immediate feedback from electroencephalogram (EEG) sensors embedded in 
a bicycle helmet. For example, when they succeeded in increasing their beta- to theta-wave ratio, they earned 
points in the computer game.21
In the cognitive training program, meanwhile, children completed 14 different computerized tasks 
targeting attention, working memory and impulsivity.18 When children succeeded at a task, such as matching 
letter-number pairs, they earned virtual prizes. The tasks automatically became more challenging as children’s 
skills progressed. 
For both neurofeedback and cognitive training, children participated in 40 training sessions at their school 
lasting 45 minutes each.18 A research assistant was available during all training sessions to provide minimal 
help, if needed. Children in both programs were also encouraged to continue with any other treatments they 
were already receiving, including medications.
Table 3 describes the three child-focused approaches and their evaluations. The table also describes the two 
parent-centred interventions, outlined in the two subsequent paragraphs.
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Substantial 
research supports 
the effectiveness 
of parent training 
interventions for 
childhood ADHD.
 
Table 3: Psychosocial Treatment Evaluations 
Child  
ages
8 –12 years
 
 
7 –11 years 
5 –18 years
 
 
8 –12 years
Sample  
size
89
 
 
104
81
 
 
72
Program 
(Country)
Braingame Brian 17 
(netherlands) 
Neurofeedback 18 
or
Cognitive Training 18 
(Us)
 
Psychoeducation 
(spain)19
 
 
Strongest Families  
(Canada)20
Delivery format 
(duration)
25 individual child sessions focused on improving memory 
+ cognitive ability + stopping impulsive responding; using a 
computer game at home (5 weeks)
40 individual child sessions focused on increasing attention;  
using a computer game with eeG sensors in schools (5 months)
40 individual child sessions focused on increasing attention + 
memory through a variety of exercises; using a computer game  
in schools (5 months)  
 
12 group educational family sessions focused on information 
about adhd + behavioural strategies for managing symptoms + 
reducing defiant behaviour; delivered in a community clinic  
(3 months)
12 self-directed parenting sessions focused on behavioural 
strategies; supported by 14 telephone coaching sessions; 
predominately self-delivered in homes (3 months)
Parent-Focused Treatments
Child-Focused Treatments
Both of the parent-focused treatments concentrated on helping caregivers manage children’s ADHD 
symptoms. In the psychoeducation program, groups of eight to 10 families participated in nine sessions, 
receiving information about ADHD.19 These sessions were followed by three sessions addressing a variety of 
behavioural strategies for managing ADHD symptoms and reducing defiant behaviour. 
The other parent-focused program, Strongest Families, differed in its focus and delivery. 
Parents were taught behavioural strategies including creating positive relationships with their 
children through noticing and consistently rewarding their positive behaviours.20 Positive 
communication strategies — such as alerting children to upcoming transitions and working with 
schools — were also stressed. Parents worked through handbooks and videos at home over a  
12-week period, supported by 14 telephone calls from program coaches.20
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Determining what works
Most of the RCTs assessed a variety of outcomes beyond ADHD symptoms, such as oppositional behaviours, 
memory and executive functioning. Given the purpose of our review, however, we report only on child 
ADHD outcomes at final follow-up. As well, many of the outcome measures reported were behavioural 
rating scales that included an overall score (e.g., total ADHD symptoms) as well as subscale scores (e.g., 
hyperactivity/impulsivity and inattention). In such situations, we report findings from the total score only. 
For all reported findings, we also classify outcomes as being “positive” when researchers found statistically 
significant differences favouring the intervention over the control condition. Where available, we also report 
the degree of clinical improvement, or effect size, for a given intervention.
A new medication option?
The study that assessed guanfacine’s effectiveness when used independently showed significant benefits.14 
Specifically, children on guanfacine had fewer clinically significant ADHD symptoms, as evidenced by 
a large effect size, compared to placebo.14 ADHD symptom severity was also reduced for children on 
guanfacine compared to placebo. In addition, guanfacine led to more children having improved symptoms 
overall — 67.9% versus only 44.1% for children on placebo. Finally, children on guanfacine experienced less 
impairment in daily living, including functioning better at school and in social activities.
This guanfacine study also assessed side effects comprehensively, using laboratory 
tests, physical examinations and rating scales.14 Overall, 77.2% of children on guanfacine 
reported side effects, compared to 65.8% of children who took placebo.14 However, the 
authors did not assess whether these differences were statistically significant. Drowsiness 
(43.9%), headaches (26.3%) and fatigue (25.4%) were the most commonly reported 
symptoms for children taking guanfacine. Notably, nine of the 114 children assigned to 
guanfacine (or 8%) discontinued the medication because of side effects. 
Does adding medication add benefits?
The study that assessed guanfacine when taken in addition to extended-release methylphenidate or 
dextroamphetamine also showed significant benefits.15 Specifically, children receiving guanfacine adjunctively 
showed significant reductions in ADHD symptoms — with small-to-moderate effect sizes — compared to 
children taking a psychostimulant and a placebo (the comparison group). These children also had less severe 
ADHD symptoms, with 42.3% to 51.4% falling in the “normal to borderline range,” compared to 32.9% in 
the comparison group.15
This guanfacine study also assessed side effects comprehensively, using laboratory tests and physical 
examinations.15 Children on guanfacine as an adjunct to psychostimulants experienced more side effects 
than children who took only psychostimulants and a placebo — 76.3% to 77.3%, compared to 63.4% 
for psychostimulants plus placebo.15 (The authors did not assess whether these differences were statistically 
significant.) Headaches (21.2%), drowsiness (13.6%) and upper respiratory tract infections (9.9%) were 
the most common side effects for guanfacine. Ten of the 302 children assigned to guanfacine (or 3%) 
discontinued the medication because of side effects. 
 There are only  
two RCTs on 
guanfacine, and both 
involved significant 
ties to the drug 
manufacturer.
r e v i e W
Table 4 summarizes the findings for both guanfacine studies. 
 
* all listed outcomes were statistically significant for intervention children compared with controls.
** adhd symptoms including inattention, hyperactivity and impulsivity were measured using a single scale or interview.
 
Table 5: Psychosocial Treatment Outcomes
Child-Focused Treatments
No significant difference 
inattention
Hyperactivity/Impulsivity
none
 
inattention
Hyperactivity/Impulsivity
adhd symptoms** 
adhd symptom severity
adhd symptom improvement
Hyperactivity/Impulsivity
none 
Positive child outcomes*
none
	inattention
	Hyperactivity/Impulsivity (2 measures) 
none 
	inattention
	
	adhd diagnoses
Follow-up
3 months
 
6 months
12 months
 
5 months
Program
Braingame Brian 17 
Neurofeedback 21 
Cognitive Training 21
 
Psychoeducation19 
 
 
Strongest Families 20
Parent-Focused Treatments
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Table 4: Guanfacine Outcomes
No significant difference 
none
 
 
 
none 
Follow-up
Post-test (children had 
been on medication for 
between 10 and 
13 weeks)
Post-test (children had 
been on medication for 
8 weeks)
Format
Guanfacine alone 14
 
 
 
Guanfacine  
adjunctive to a 
psychostimulant 15
Positive child outcomes*
   adhd symptoms**
	adhd symptom severity
  adhd symptom improvement 
  Functioning 
	adhd symptoms**
	adhd symptom severity
  adhd symptom improvement
* all listed outcomes were statistically significant for intervention children compared with controls.
** adhd symptoms including inattention, hyperactivity and impulsivity were measured using a single scale or interview.
 
Building children’s skills
We found considerable variation in outcomes for the three child-focused programs. Braingame Brian resulted 
in no significant differences on measures of inattention or hyperactivity/impulsivity for intervention children 
compared to controls at three-month follow-up.17
For neurofeedback, however, significant positive results occurred at six-month follow-up.21 Children 
receiving this intervention had fewer symptoms of inattention (by parent report, albeit with a small effect 
size).21 They also had fewer symptoms of hyperactivity/impulsivity (by parent report, with a small effect size, 
and by researchers’ classroom observations, where effect size was not reported). In contrast, the other program 
evaluated in this RCT — cognitive training — did not improve any child ADHD outcomes.21
Table 5 summarizes the findings for the three child-focused programs. It also summarizes findings for the 
parent-focused programs, which are described next. 
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How can parents help? 
Both parent-focused interventions produced benefits for children. One year after the psychoeducation 
program ended, children of participating families had significantly fewer symptoms of inattention, based on 
parent reports. The degree of clinical improvement for this outcome was moderate. However, when the study 
authors took the added step of conducting multiple statistical analyses, inattention was no longer significant. 
As well, the program did not produce substantial gains for any other ADHD-related outcomes, including 
overall symptoms, symptom severity or improvement, or hyperactivity/impulsivity-specific symptoms, by 
either parent or clinician report.19
The Strongest Families evaluation was the only RCT that assessed children’s diagnostic status — the 
most robust outcome indictor when testing treatments. At five-month follow-up, children whose parents 
participated in the program were significantly less likely to meet ADHD diagnostic criteria compared to 
controls.20 In fact, Strongest Families children had less than half the odds of receiving an ADHD diagnosis  
(see Table 5).
Recapping the results
Of the six treatments evaluated in our review, three showed 
particularly strong benefits. The medication guanfacine effectively 
reduced ADHD symptoms when used independently or when 
used adjunctively with psychostimulant medications. However, 
these findings need to be viewed with caution. The drug 
manufacturer was involved in study design, data collection, data 
analyses and interpretation in both studies. As well, all study 
authors had financial ties to the drug company. Additionally, 
guanfacine was associated with side effects, particularly headaches 
and drowsiness. Further evaluations are therefore warranted.
Beyond medications, of the three child-focused programs, 
only neurofeedback produced positive outcomes for ADHD 
symptoms. This program reduced inattention as well as 
hyperactivity/impulsivity. Although both parent-focused 
programs also produced some benefits, Strongest Families stood 
out. This Canadian program significantly reduced the number 
of children meeting diagnostic criteria for ADHD — a robust 
outcome indicator. 
Implications for practice and policy
Combining our current review and our previous two Quarterly issues on ADHD treatments, we have now 
examined nearly 40 years of research. This large body of evidence suggests three recommendations for practice 
and policy. 
•  Build on the power of parenting. Substantial research supports the effectiveness of parent training 
interventions for childhood ADHD. These programs teach positive behavioural strategies, such as 
consistently noticing and rewarding children when their actions are constructive. Among these programs, 
Strongest Families stands out for its ability to reduce the number of Canadian children with ADHD 
diagnoses. Essential elements of this program are home delivery using parent handbooks and videos, 
Who’s still footing the bill?
in our spring 2013 issue, we identified concerns with drug companies funding evaluations 
of medications that they produce and sell, 
including past attempts to stop the publication 
of unfavourable results.9 While steps have been 
taken to address some conflicts of interest, 
including certain journals requiring conflict-of-
interest declarations, challenges remain. the drug 
manufacturer’s involvement in the guanfacine 
studies cited in this issue is a good example. We 
decided to retain these two studies, however, while 
identifying our concerns with them. Children are 
being prescribed these medications, so families 
and practitioners need to know about the findings 
and the issues. still, we echo the calls that others 
have made for governments and non-commercial 
sponsors to increase their funding of independent 
drug evaluations, including requiring independent 
trials for drug approval from regulatory agencies  
— particularly for drugs prescribed for children.23
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an excellent format for reaching traditionally underserved children and families such as those in rural 
or remote communities; telephone coaching to support parents; and its brief format, offering sessions 
over just three months. Communities and organizations may also want to consider implementing other 
effective behaviourally based parent training interventions, including those that offer in-person support. 
Adaptations may need to be considered to ensure that any programs implemented are culturally relevant. 
•  Help children develop new skills. A number of effective interventions can also be delivered directly 
to children. The evidence supporting child CBT and behavioural therapy is particularly strong, spanning 
many studies now, and evidence on neurofeedback is also starting to emerge. Unlike medications, these 
psychosocial treatments have the added advantage of continuing to show benefits months after the 
intervention ends. Another advantage for both CBT and behavioural therapy is that many practitioners 
are familiar with these interventions, making their implementation feasible. Child CBT and behavioural 
therapy are therefore highly recommended. 
•  Use the right medications, and use them carefully. Many children with ADHD require 
medication, even with psychosocial treatments in place. The medications methylphenidate, 
dextroamphetamine and atomoxetine all have strong evidence of success. As well, two recent preliminary 
evaluations showed that guanfacine is effective — on its own and adjunctively for children with 
suboptimal responses to psychostimulants. However, there are only two RCTs on guanfacine, and both 
involved significant ties to the drug manufacturer. So caution and further research are warranted for 
this medication. Practitioners who prescribe any ADHD medications need to carefully track children’s 
responses, including evaluating efficacy as well as side effects on an ongoing basis. 
Forty years of research have shown that many effective treatments exist for childhood ADHD. 
Practitioners can offer children and families a range of good options, such as parent training and child CBT 
and behavioural therapy, coupled with appropriate medications (and monitoring) when needed. Policy-makers 
can also support children — by ensuring that effective treatments are made widely available. This is good news 
for BC children with ADHD.
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m et h o d s
• CINAHL, ERIC, Medline and PsycINFO  
• ADHD or attention-deficit/hyperactivity disorder or attention deficit or attention 
disorder or hyperkinesis and treatment or intervention or train*  
• Peer-reviewed articles published in English between 2011 and 2016 (for 
psychosocial and dietary supplements) or before May 2016 (for guanfacine) that 
were either original rCts or follow-up rCts
• Children aged 18 years or younger
Table 6: Search Strategy
Sources
 
Search Terms 
Limits
* For our search for psychosocial interventions, we added the term “not pharmacological or medical”; for our 
guanfacine search we added “guanfacine.”
Table 7: Inclusion Criteria for RCTs  
• Clear descriptions were provided of participant characteristics, settings and interventions
• Interventions were evaluated in a high-income country* for comparability with Canadian policy and 
practice settings 
• Interventions aimed to treat childhood ADHD
• At study outset, most study participants had an ADHD diagnosis
• Child outcome indicators included diagnoses and/or symptoms of ADHD
• Reliability and validity of all primary outcome measures or instruments was documented
• Levels of statistical significance were reported for primary outcome measures
Psychosocial Treatment Studies
• Participants were randomly assigned to intervention and control groups at study outset
• Follow-up was three months or more (from the end of the intervention) 
• Attrition rates were below 20% at follow-up and/or intention-to-treat analysis was used
• Child ADHD outcomes were assessed at follow-up using two or more informant sources 
• At least one outcome rater was blinded to participants’ group assignment
Medication and Dietary Studies
• Participants were randomly assigned to intervention and placebo groups at study outset
• Attrition rates were below 20% at post-test and/or intention-to-treat analysis was used
• Child ADHD outcomes were assessed at post-test using two or more informant sources 
• Double-blinding procedures were used
• Side effects and adverse reactions were comprehensively assessed and reported 
* according to World Bank standards. 
We used systematic review methods adapted from the Cochrane Collaboration and Evidence-Based Mental Health. First, we conducted a search to identify high-quality research evidence on the effectiveness of interventions aimed at treating attention-deficit/hyperactivity disorder (ADHD) 
in children. We then built quality assessment into our inclusion criteria to ensure that we reported on the best 
available evidence. For example, we required that studies used randomized controlled trial (RCT) methods. To 
update our previous work, we limited our search to psychosocial treatments, with the exception of a separate 
search for guanfacine RCTs. Our search strategy is detailed in Table 6.
Using these approaches, we identified 88 RCTs with potential relevance. Two team members then 
independently assessed each RCT, finding six that met all our inclusion criteria, detailed in Table 7.
Data from these RCTs were then extracted, summarized and verified by two or more team members. 
Throughout our process, any differences between team members were resolved by consensus.
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2 – Children’s behavioural wellbeing 
1 – Prevention of mental disorders
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